09:00 - 17:30 EST | 6.00 - 14.30 PST

* Please note that the following agenda timings are Eastern Standard Time.  

For full agenda session details and Pacific Standard Times, please download the full event guide here

8:20 am Chair’s Opening Remarks

  • Scott Boiko Associate Director Translational Science, Forma Therapeutics

Optimizing Model Characterization & Validation Methods for Translational Relevancy & Predictivity

8:30 am Modelling Small Cell Lung Cancer in Preclinical Development of Synthetic Oncolytic Virus


  • Tumor heterogeneity of small cell lung cancer tumors is challenging to recapitulate in a single preclinical model
  • To better model the complexity of SCLC tumor and microenvironment and to improve translation of preclinical findings into clinic Oncorus employed a number of models including cell- and patient- derived tumor xenografts, GEMMs and
    humanized mouse tumor models
  • Based on in vitro studies of the replication of oncolytic virus, sensitive models were identified, and successfully implemented in vivo identifying treatmentresponsive PDXs

9:00 am Applying Real-World Data & Tumor Modeling to Discovery & Translational Research

  • Julie Gerardi VP, Viological Modeling & Functional Genomics Business Development, Tempus


Learn how Tempus uses real-world data and three-dimensional tumor modeling to advance discovery and translational research for targeted therapeutics in oncolog

9:15 am Roundtable: Outlining Model Validation & Establishing the Need for Standardization

  • Scott Boiko Associate Director Translational Science, Forma Therapeutics


  • How to effectively identify novel drug combinations on a limited experimental budget
  • Common pitfalls in phenotypic drug combination screening analysis – can we move away from computed synergy scores
  • Avoiding bias when evaluating drug combinations in vivo

10:00 am Translating Preclinical Combinatorial Therapy Approaches in In Vitro & In Vivo Models of Human Glioblastoma Multiforme

  • Monika Buczek PhD, Director of Business Development, Business Development


  • Identification of potentially efficacious agents via NCI drug library and drug-gene network analysis using GBM spheroids developed from primary patient tissue
  • Are single agent and combinatorial effect predictions correct when tested in an in vitro setting?
  • Will in vitro single and combination agent efficacy data translate into in vivo pharmacology models?
  • Does reverse translation of in vivo PDX tumors recapitulate prior in vitro results?

10:15 am Morning Break & Structured Networking


Here we will announce the winner of the poster session!

10:45 am Combination Approach: Using Chicken Egg In vivo assay for High-Value Identification of Oncology and Immuno-Oncology drugs Candidates


  • How to use INOVOTION’s technology to open new perspectives of in vivo screening in oncology and immuno-oncology
  • Why does the chicken embryo model have several advantages for drug discovery of anti-cancer treatments over traditional in vivo models?
  • The chicken embryo model fills the gap between in vitro studies and in vivo mouse models, but is it possible to predict mouse data from chicken embryo results?

Rethinking our Model Selection Strategies

11:15 am Weighing up Pros & Cons of Quick & Dirty Models Versus Slower Growing Models


  • Establishing the difficulty in balancing model complexity, time and costs
  • What is the role of longer timeline tumor models? Can these help to answer questions about sequencing?
  • Advantages and disadvantages of different models, including PDX, syngeneic, and electroporation-based genetic transfer

11:45 am Orthotopic & Metastatic Xenograft Studies in the SRG Rat

  • Matthew Hebb Neurosurgeon Scientist, University of Western Ontario


The SRG rat is an ideal highly immunodeficient xenograft host which provides advantages for preclinical in vivo drug efficacy studies including higher tumor takerates, serial tumor biopsies, and combination metabolism/safety studies. Hera
will present data on novel applications of the SRG rat including metastatic and orthotopic tumor models

12:00 pm The Disease Model Finder: An AI-Powered Platform to Enhance Disease Model Sourcing


  • Scientist.com – world’s leading and fastest-growing marketplace for outsourced scientific services and products
  • Disease Model Finder – an AI solution to accelerate tumor model sourcing from industry leading providers
  • Leveraging the Disease Model Finder’s user-friendly bioinformatic functionality to compare tumor models across suppliers and expedite your timelines

12:15 pm Networking Lunch

Incorporating the Immune System & Tumor Microenvironment

1:15 pm Retaining the Tumor Immune Microenvironment Heterogeneity & Vascular Cross-talks in Ex-Vivo Microphysiological Models

  • Marco Campisi Postdoctoral Research Fellow, Dana-Farber Cancer Institute


  • Focusing on the need to represent the tumor heterogeneity and vascular interaction to investigate the effect of cellbased cancer immunotherapies in thoracic malignancies
  • Co-opting innate immunity and vascular barrier to target solid tumors
  • Exploring next generation microphysiological systems to recapitulate more relevant human models in vitro vs animal systems

1:45 pm Model Selection for Tumor Heterogeneity & TME


  • Discuss how to select the right model to capture tumor heterogeneity
  • What are the advantages and disadvantages of: wild-type mice, surrogate models, GEMM, syngeneic
  • What are the most translatable models when it comes to the tumor microenvironment?

Focusing on Translatability, Tackling Drug Resistance & Tumor Transporter

2:15 pm MATCH-R: A Preclinical Platform of Resistant Models to Innovative Therapies • Highlighting the development of a panel


  • Highlighting the development of a panel of PDX models and organoids derived from biopsies collected at the stage of acquired resistance
  • Demonstrating how these preclinical models will be used to improve knowledge on the mechanisms underlying resistance to treatment
  • Exploring the impact on evaluating response to new treatment

2:45 pm 3D Screening Model for Combination Drugs Against Tumor Differentiated & Undifferentiated Cells


  • Delving into patient resistance after targeted therapy
  • Overcoming drug resistance with 3D models that enable drug screening against undifferentiated and differentiated cells in the tutor tissue
  • Outlining nanostructured delivery systems to target drugs to cancer cells

3:15 pm Afternoon Break

Exploring 3D Models – Advantages & Disadvantages

3:45 pm Panel Discussion – What Are the Advantages of 3D Models

  • Marco Campisi Postdoctoral Research Fellow, Dana-Farber Cancer Institute
  • Juan Arriaga Assistant Professor – Department of Oncological Sciences & Urology, Icahn School of Medicine at Mount Sinai
  • Katie Grausam Postdoctoral Scientist, Cedars Sinai


  • Can we use organoids as the first approximation of what’s going to happen in vivo?
  • Do 3D models offer the opportunity to mix and match your input cells to assess whether certain cell populations are influencing response?
  • The 3 R’s: are 3D models paving the way for reduction, refinement and replacement?
  • How can we incorporate the TME into 3D models?

4:15 pm Breaking Down Barriers In Immune-Excluded Tumor Biology


  • Immune exclusion in tumors has been associated with unfavorable clinical outcome and poor response to therapy
  • Therapies targeting immune exclusion are orthogonal to cancer immunotherapy and could improve responses
  • DDR1 as an example of a druggable target implicated in establishing mechanical barriers for an immune response

4:45 pm Chair’s Closing Remarks & End Of Summit

  • Scott Boiko Associate Director Translational Science, Forma Therapeutics